Skip to main content

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

  • U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma
  • CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France
  • CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patients
  • The company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 
  • The FDA has granted Berubicin Fast Track and Orphan Drug status, speeding the possibility of marketing the drug following the potentially pivotal clinical review

Innovative brain tumor therapy developer CNS Pharmaceuticals (NASDAQ: CNSP) is reporting continued expansion of the number of clinical site launches for its evaluation of the company’s lead product candidate for treating recurrent glioblastoma multiforme (“GBM”).

CNS Pharmaceuticals noted in a recent update about its anti-cancer drug candidates and its third quarter financial results that the potentially pivotal trial for its lead candidate — Berubicin — has begun patient enrollment and dosing in France, bringing its operational tally to 29 of 68 clinical sites now enrolling…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.